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Abstract: This article reports on the effects of a new combined wet milling technique on the
physicochemical properties of meloxicam (MEL). The influence of milling time on the particle
size, the crystallinity, the morphology and the dissolution rate of MEL has been studied in the
presence and absence of polyvinyl alcohol (PVA) as a stabilizer agent. Micronized MEL particles
were produced in aqueous medium which did not contain additive after milling for 10 min. For
nanonization an additive and longer milling time were required. After particle size determination
the structural and morphological characterization of the wet milled, dried products containing MEL
were studied. X-ray powder diffractometry (XRPD) and differential scanning calorimetry (DSC)
examinations revealed the change in the crystallinity of MEL. Scanning electron microscopy (SEM)
images showed that aggregates of nanosized MEL particles were formed, regardless of the presence
of PVA. The nanonized MEL crystals (D50 = 126 nm) exhibited a regular shape and a smooth surface.
The increased specific surface area resulted in a high dissolution rate and concentration of free MEL.
According to the results, the produced samples could be applied as a basic material (micronized MEL)
and intermediate product (micronized and nanonized MEL with PVA) for the design of dosage forms.
Keywords: wet milling; micronization; nanonization; physical structure; crystallinity; in vitro dissolution
1. Introduction
One of the major current challenges of the pharmaceutical industry is related to strategies that
improve the water solubility of drugs because over 40% of new drug candidates are water-insoluble
compounds [1]. Poorly water-soluble drug properties can impede the effective delivery of these drugs
into humans, and affect their dissolution rate and subsequent absorption at the site of activity [2].
Poorly soluble molecules have been successfully formulated by employing a variety of
techniques to modify the physico-chemical and biopharmaceutical properties of drugs [3,4] such as:
(i) solubilization in surfactant solutions; (ii) use of co-solvents [5], salt formation [6], complexation
with cyclodextrins [7], crystallization [8], amorphization [9], milling [10], etc.
Milling is a technique commonly applied to produce micro- or nanosized drug crystals in order to
increase the dissolution rate and absorption, and hence the bioavailability of poorly-soluble materials.
According to the Noyes-Whitney equation, the reduction of the particle sizes of drug crystals increases
the specific surface area, which can improve the rate of dissolution of the drug [11]. There are many
different well-known types of milling techniques with both advantages and disadvantages; dry and
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wet milling can be distinguished [12,13]. Wet milling requires less energy and time than dry milling.
Thanks to the environmentally isolated system, it is a dust free process and the material is less heated
up [14]. However, wet milling has some disadvantages as well, e.g., increased wear of the grinding
medium, corrosion hazards, etc. To overcome the limitations of the conventional particle size reduction
technologies for poorly-soluble drugs, new combinational methods have been developed for the
production of ultra-fine suspensions. These technologies are a relatively new approach to improve
the effectiveness of particle size reduction and to reduce the time of processes. In general, they can
be described as a combination of a bottom-up process (the building-up of particles) [15–17] followed
by a top-down technology (disintegration) [18,19]. This method involves two particle size reduction
steps. There is also a possibility for the combination of dry- and wet milling in one step, but literature
data relating to the application of this combined method are lacking. Retsch GmbH (Haan, Germany)
has recommended the combination of planetary ball milling, as dry milling, and pearl milling, as wet
milling [20] techniques.
In wet micro- and nanonization, the application of additives is required in order to retain
the individuality of the particles. Different additives are used to stabilize these particles:
poly(vinylpyrrolidone) (PVP), Poloxamer® (Poloxamer 188 = poly(ethylene)–poly(propylene glycol),
polysorbate (Tween 80® = poly(oxyethylenesorbitan monooleate)), Solutol® (Solutol HS 15 =
poly(ethylene glycol 15-hydroxystearate)), PVA (poly(vinyl alcohol)), etc. [21].
Milling and the presence of additives during milling have the ability to decrease the crystallinity
of active materials [22,23]. The amorphous phase transition usually results in improved dissolution
rates, thereby increasing the bioavailability, with the improvement being directly related to the extent
of amorphization [24]. However, physical and chemical instability of amorphous material could
be expected.
Meloxicam (MEL) is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory,
analgesic and antipyretic effects. MEL was chosen as a model crystalline drug because of its poor
aqueous solubility (4.4 µg/mL) [25] and relatively high melting point (270 ˝C) [26].
This research investigates the applicability of a wet milling method combining planetary ball
and pearl milling. We set out to utilize particle size reduction to the micro- or nanometre range. The
effects of milling time and the presence or absence of stabilizer (PVA) in reducing the particle size were
investigated. The changes in crystallinity and morphology of MEL during milling have been studied.
The effects of particle size reduction and amorphization on the dissolution rate were determined.
2. Results and Discussion
2.1. Effects of Milling Time on Particle size Distribution (PSD) and Specific Surface Area (SSA)
During our work, a combined wet milling technique (planetary ball mill and pearls, as milling
media) was investigated. Analysis of the laser diffraction results revealed that the milling in the case
of samples containing water as a dispersant medium resulted in a roughly 85% decrease in average
MEL particle size. The D10, D50 and D90 values and the SSA are reported in Table 1.
After 10 min milling, micronized MEL was observed. However, further milling led to an increase
in particle size, because MEL particles aggregated without the presence of PVA. The smallest average
particle size (3.55 µm) and the highest SSA (1.89 m2/g) were obtained during the first 10 min of
milling. During milling heat production was observed and the temperature of the samples increased
up to 40–45 ˝C. The aqueous solubility of MEL (4.4 µg/mL, 25 ˝C) increased due to the elevated
temperature (40 µg/mL, 37 ˝C), but it was not remarkable in our investigation (at about 0.04 w/v%),
and 0.8 mg MEL could be dissolved in our dispersant medium (water) of the presence 2 g of active
agent. The recrystallization of the small amount of dissolved MEL was irrelevant in terms of any
particle size increase.
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Table 1. MEL PSD and SSA in pre-dispersions containing water as dispersant.
Milling Time (min) D10 (µm) D50 (µm) D90 (µm) SSA (m2/g)
raw MEL 11.40 34.26 73.59 0.332
10 1.76 3.55 8.69 1.89
20 2.63 5.74 14.21 1.22
30 2.62 5.99 18.97 1.18
40 2.77 6.84 24.54 1.07
50 2.72 6.13 19.56 1.15
60 2.57 6.12 20.87 1.18
70 2.77 7.13 26.26 1.05
80 2.58 5.94 22.54 1.19
90 2.51 5.55 18.88 1.25
In the case of PVA-solution as a dispersant, after 10 min micronized, and after 50 min nanonized
particles were noted, with monodisperse PSD (Table 2). The average particle size decreased efficiently,
from approximately 35 µm to 126 nm, up to 50 min of milling. The SSA of MEL rose 150-fold compared
to the raw MEL. Further milling led to only a slight decrease in particle size. PVA, used as a coating
polymer helped the particles to separate from each other. Aggregation was also prevented, therefore
the stability of the system could be improved.
Table 2. MEL PSD and SSA in pre-dispersions containing PVA-solution as dispersant.
Milling Time (min) D10 (µm) D50 (µm) D90 (µm) SSA (m2/g)
raw MEL 11.40 34.26 73.59 0.332
10 0.24 2.96 29.40 7.71
20 0.084 0.169 2.863 34.6
30 0.090 0.337 4.180 27.2
40 0.074 0.134 1.358 46
50 0.074 0.126 0.253 49.5
60 0.072 0.122 0.219 52
70 0.070 0.121 0.225 52.6
80 0.072 0.119 0.209 53.2
90 0.064 0.116 0.219 57.9
2.2. Characterization of the Dried Products
2.2.1. Physical Structure (XRPD and DSC)
For determination the effect of milling on the crystallinity of MEL pre-dispersions, samples milled
for 10 min in water as a dispersant, and for 10 and 50 in PVA-solution as a dispersant were dried
and characterized.
The XRPD diffractogram of raw MEL and of MEL in the physical mixture of MEL-PVA
demonstrated its crystalline structure, as expected. The characteristic peaks are located at the following
2θ values: 13.22˝, 15.06˝ and 26.46˝. Ten min of milling in the water-containing sample caused the
loss of the crystalline structure of the drug, and only 3% of the drug remained crystalline (Table 3).
The intensities of the characteristic peaks were decreased in the case of the treated product (Figure 1).
During the further milling aggregation was observed, because of the lack of PVA. At the end of milling
(90 min), 9% of MEL remained crystalline.
In the PVA-solution containing sample in the course of milling, a decrease in crystallinity was
perceptible. After milling for 10 min, ~47% of the drug remained crystalline. After 90 min milling
amorphization was detected, the degree of crystallinity was 2% (Table 3). The intensities of the
characteristic peaks decreased due to the milling (Figure 2).
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DSC was employed to investigate the melting of MEL in the raw form, the physical mixture and
in the milled dried products (Figure 3). The DSC curves of the raw MEL and of MEL in the physical
mixture of MEL-PVA revealed a sharp endothermic peak at 259.1 and 255.9 ˝C, reflecting its melting
point and confirming its crystalline structure. In case of water-containing samples the most significant
decrease of crystallinity was observed after 10 min milling (peak: 227.0 ˝C). Increasing the milling
time, aggregation was detected. Using PVA-solution as dispersant, DSC curves exhibited a broad
endothermic peak for MEL, indicating that the crystallinity of the drug was decreased (Table 4). The
residual MEL crystals in the products melted at a lower temperature than the crystals of raw MEL due
to the smaller particle size and the increased degree of amorphization which was directly proportional
to the duration of milling. This process was promoted by PVA, which was softened at 43 ˝C as glass
transition temperature (Tg) value.
Molecules 2016, 21, 507 5 of 11 
 
  l   i i   l i    i    ,  i l i   
i   ill  i   i  .           i   i l 
i    l   s  i    .   .  ° , fl i  i  l i  
i t  fi i  it  t lli  t t . I   f t - t i i  l  t  t i ifi t 
 f t lli it    ft   i  illi  ( : .  ° ). I i  t  illi  
ti , ti   t t . si  - l ti   i t,   i it    
t i   f  , i i ti  t t t  t lli it  f t     ( l  ).  
i l  crystals in the products melted at a lower temperature than the cry tals of raw MEL 
due to the sm ller particle size a d th  increased degree of amorphization which was directly 
proportional to the duration of milling. This process was promoted by PVA, which was softened at 
43 °C as glass transition temperature (Tg) value. 
 
Figure 3. DSC curves of MEL_raw, MEL_PVA_pm, MEL_W 10 min, MEL_W_PVA 10 min and 
MEL_W_PVA 50 min. 
Table 4. Thermoanalytical evaluation of MEL_raw, MEL_PVA_pm and dried milled products. 
Parameters Raw MEL pm Dried MEL_W Samples Dried MEL_W_PVA Samples
Milling time (min) - - 10 50 60 90 10 50 60 90
∆H * (J/g) −148.5 −29.9 −7.5 −40.1 −64.4 −40.8 −60.3 −70.9 −32.4 −46.4 
Onset (°C) 258.4 235.9 217.9 233.5 248.5 247.1 231.6 232.9 207.1 206.2 
Peak (°C) 259.1 255.9 227.0 238.7 250.7 250.2 239.8 240.1 216.7 217.4 
Endset (°C) 261.0 255.9 230.0 240.4 250.8 251.6 243.1 243.2 222.3 222.3 
* ∆H: normalized integral. 
It can be concluded that combined milling resulted in partial amorphization of MEL which could 
results in a higher dissolution rate compared to the raw drug and its physical mixtures. 
2.2.2. Particle Shape and Size 
In the following SEM images (Figure 4) the morphology of the modified particles is demonstrated. 
Dried products produced by milled pre-dispersion in water for 10 min and MEL micronized and 
nanonized in the presence of PVA (10 and 50 min) were investigated. How the surface and shape 
changed after the milling process, compared with raw MEL, was checked. After taking samples after 
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MEL_W_PVA 50 min.
Table 4. Thermoanalytical evaluation of MEL_raw, MEL_PVA_pm and dried milled products.
Parameters Raw MEL pm Dried MEL_W Samples Dried MEL_W_PVA Samples
Milling time (min) - - 10 50 60 90 10 50 60 90
∆H * (J/g) ´148.5 ´29.9 ´7.5 ´40.1 ´64.4 ´40.8 ´60.3 ´70.9 ´32.4 ´46.4
Onset (˝C) 258.4 235.9 217.9 23 .5 8.5 2 .1 23 . 23 . 20 . 20 .
Peak (˝C) 259.1 255.9 227.0 238.7 250.7 250.2 239.8 240.1 216.7 217.4
Endset (˝C) 261.0 255.9 230.0 240.4 250.8 251.6 243.1 243.2 222.3 222.3
* ∆H: normalized integral.
It can be concluded that combined milling resulted in partial amorphization of MEL which could
results in a higher dissolution rate compared to the raw drug and its physical mixtures.
2.2.2. Particle Shape and Size
In the following SEM images (Figure 4) the morphology of the modified particles is demonstrated.
Dried products produced by milled p -dispersion in water for 10 min and MEL micronized and
nanonized in the presence of PVA (10 an 50 m n) were investigated. How the surfa e and sh pe
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changed after the milling process, compared with raw MEL, was checked. After taking samples after
10 min of milling in the case of water as a dispersant and 10 and 50 min of milling in the case of
PVA-solution as the medium, the suspensions were dried and characterized. The raw MEL consisted
mainly of angular, prismatic crystals with a broad size distribution. In the case of the water-containing
samples, it was shown that micro-sized aggregates consisting of nanonized particles were formed.
In the case of PVA-solution-containing sample, 10 min of milling resulted in irregular particle shapes,
with the approximately 3 µm D50 value. MEL crystals could be detected between the amorphous
PVA particles. After 50 min, nanonized MEL crystals (at about 120 nm) embedded in the PVA-film,
with regular shape and smooth surface were perceived. The particle endurance during the treatment
accounts for the smooth surfaces of the particles.
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2.2.3. In Vitro Dissolution Tests
The in vitro dissolution test was performed at pH 7.4, which could represent the media of the
intestinal system where the absorption of MEL could be totally achieved. At pH 7.4 the conditions
of the lung, nasal and skin epithelia could also be imitated. The in vitro dissolution showed the poor
solubility and slow dissolution of MEL (D50 = 34.26 µm), and after 60 min approximately 10%, and
after 2 h around 22% of the drug was liberated. Application of PVA (in the reference sample, where
the size of the MEL did not decreased significantly) as hydrophilic wetting agent, could improve
the dissolution rate by 2-fold. The micronization of the drug without PVA (D50 = 3.55 µm) could
influence the dissolution rate 3-fold. Producing individual micronized (D50 = 2.96 µm) and nanonized
(D50 = 0.126 µm) MEL drug particles in the presence of PVA, the extent of dissolution was enhanced
significantly by the increased specific surface area. The amorphous character and the submicron range
of the drug resulted in a very fast dissolution, with more than 70% of MEL liberated after the first
5 min (Figure 5).
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3.2.1. Combined Milling
A wet milling technique (a combination of planetary ball and pearl milling) was employed.
The drug (2 g) was first suspended in the dispersant medium (18 g), consisting of water and
aqueous solution of PVA (the use of lower concentrations of PVA led to extensive aggregation of
the MEL particles because of the lesser effectiveness in overcoming the cohesive forces). The resulting
suspensions (10% drug content) were wet milled at 400 rpm in the milling chamber (50 mL) of a
planetary ball mill (PM 100 MA, Retsch GmbH, Haan, Germany). The milling balls were 0.3 mm ZrO2
beads. As a preliminary experiment, the effects of different pearl weights (10, 20, 50 and 150 g) on
the particle size reduction were investigated, and milling was also carried out without pearls as a
benchmark. The most effective milling was observed when 20 g of pearls was applied. Increasing
the weight of pearls did not result in further particle size reduction, therefore 20 g of beads were
used for further experiments. The milled suspensions were separated with a 150 µm mesh size sieve.
Suspension sampling was carried out at milling times of 10, 20, 30, 40, 50, 60, 70, 80 and 90 (end of
milling) min to perform the particle size analysis.
3.2.2. Determination of Particle Size Distribution and Specific Surface Area by a Laser Diffraction Method
The volume based particle size distribution (PSD) of the raw MEL was measured by laser
diffraction (Mastersizer 2000, Malvern Instruments Ltd., Worcestershire, UK) with the following
parameters: 300RF lens; small volume dispersion unit (2500 rpm); refractive index for dispersed
particles 1.720; refractive index for dispersion medium 1.330. The Dynamic Laser Light Scattering
method was used to determine the PSD. The particle size of the MEL was determined directly on
the initial suspension in water in which PVA was dissolved. The size analysis was repeated three
times. Water was used as dispersant medium and the obscuration was in the range 11%–16% for
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all measurements. In all cases, the volume weighted particle size distributions, D10, D50, and D90
(where for example D50 is the maximum particle diameter below which 50% of the sample volume
exists–also known as the median particle size by volume) were determined and evaluated. The specific
surface area was derived from the particle size distribution data. The assumption was made that all
the measured particles were spherical.
3.2.3. Preparation of Solid Products for Physical-Chemical Investigations of Products
After the particle size determination, the selected pre-dispersions were dried in a vacuum dryer
(Binder GmbH, Tuttlingen, Germany) at 40 ˝C in order to obtain solid products for physicochemical
investigations. The abbreviations of solid state samples are summarized in Table 5.
Table 5. Sample abbreviations.
Sample Name MEL (%) PVA (%) Description
MEL_raw 100 - untreated MEL
MEL_PVA_pm 80 20 physical mixture of MEL and PVA
MEL_W 10 min 100 - dried MEL, milled for 10 min in water
MEL_W 50 min 100 - dried MEL, milled for 50 min in water
MEL_W 60 min 100 - dried MEL, milled for 60 min in water
MEL_W 90 min 100 - dried MEL, milled for 90 min in water
MEL_W_PVA 10 min 80 20 dried product of milling for 10 min in PVA-solution
MEL_W_PVA 50 min 80 20 dried product of milling for 50 min in PVA-solution
MEL_W_PVA 60 min 80 20 dried product of milling for 60 min in PVA-solution
MEL_W_PVA 90 min 80 20 dried product of milling for 90 min in PVA-solution
3.2.4. Further Investigations of the Products
Structural Analysis
The physical state of the MEL in the samples was evaluated by XRPD. XRPD patterns were
produced with a Bruker D8 Advance diffractometer (Bruker AXS GmbH, Karlsruhe, Germany) system
with Cu K λI radiation (λ = 1.5406 Å). The samples were scanned at 40 kV and 40 mA from 3˝ to
40˝ 2θ, at a scanning speed of 0.05˝/s and a step size of 0.010˝. The crystallinity (Xc) of the MEL
in dried pre-dispersions, milled for 10, 50, 60 and 90 min was determined semi-quantitatively in
case of both dispersant medium via the mean of the decrease of the total area beneath the curve of
3 characteristic peaks (Acrystalline) compared to the raw MEL and MEL–poly(vinyl alcohol) physical
mixture (MEL_PVA_pm) (Acrystalline + Aamorphous):
Xc “
Acrystalline
Acrystalline ` Aamorphous ˆ 100 (1)
DSC measurements were carried out with a Mettler Toledo DSC 821e thermal analysis system
equipped with the STARe thermal analysis program V9.0 (Mettler Inc., Schwerzenbach, Switzerland).
Approximately 2–5 mg of pure drug or product was examined in the temperature range between 25 ˝C
and 300 ˝C. The heating rate was 5 ˝C¨min´1. Argon was used as carrier gas at a flow rate of 10 L¨h´1
during the DSC investigations.
Image Analysis (SEM)
The shape and surface characteristics of the samples were visualized by using a scanning electron
microscope (Hitachi S4700, Hitachi Scientific Ltd., Tokyo, Japan). The samples were sputter-coated
with gold–palladium under an argon atmosphere, using a gold sputter module in a high-vacuum
evaporator and the samples were examined at 15 kV and 10 µA. The air pressure was 1.3–13 MPa.
The milling-produced suspensions were dried in order to obtain solid products for SEM analyses.
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In Vitro Release
The paddle method with the USP dissolution apparatus (USP dissolution apparatus, type II
Pharma Test, Heinburg, Germany) was used to examine MEL (1.67 mg), MEL_PVA_pm and the
products (2.0875 mg). The medium was 100 mL of phosphate buffer of pH 7.4 ˘ 0.1. The basket was
rotated at 100 rpm and sampling was performed up to 120 min. After filtration (filtration pore size
0.22 µm; applying a Millex-HV syringe-driven filter unit, Millipore Corporation, Bedford, MA, USA)
and dilution, the MEL contents of the samples were determined by spectrophotometry (ATI-UNICAM
UV/VIS Spectrophotometer, Cambridge, UK) at 362 nm.
4. Conclusions
A combination of planetary ball and pearl milling (using pearls as milling media) can be applied
as a wet milling procedure to decrease the particle size and change the crystal morphology of MEL.
Wet milling in aqueous medium adheres to green technology principles as the product does not contain
organic solvent residues. Besides several advantages of wet milling, it is necessary to calculate the
wear of pearls during milling.
During our work at constant rotation rate in the presence and absence of a stabilizer, the effects
of milling time on the particle size reduction was determined (Table 6). Without additive, in the case
of water-containing samples micronization could be achieved (D50 = 3.55 µm). In the presence of
PVA, depending on the milling time, the particle size of the drug could be reduced to the micro-(after
10 min), (D50 = 2.96 µm) or nanometre range (after 50 min, D50 = 126 nm). The effect of milling on
the crystallinity of MEL was investigated. XRPD and DSC examinations revealed a decrease in the
crystallinity of MEL. In the case of water-containing samples (without PVA) aggregation occurred
during the course of milling. In the PVA-containing samples amorphization was determined (the
degree of MEL crystallinity was 2% at the end of the milling at 90 min). SEM images revealed the
aggregation of nanosized particles in water-containing samples. In the presence of additive milling
for 10 min resulted in irregularly shaped particles. The nanonized MEL crystals exhibited a regular
shape and smooth surface. The in vitro dissolution tests showed that the reduction of the particle size
of MEL, the increased SSA and the structural transformation of drug resulted in a rapid dissolution in
case of nanonized MEL-containing product. The amorphous form of the drug does not require lattice
energy to break the bonds during the dissolution process as in the crystalline state case.
Table 6. Summarized information about the determined properties of the samples.
Sample D50 (µm) Crystallinity (%) Dissolved MEL at 30 min (%)
MEL_raw 34.26 100 8.53
MEL_PVA_pm 20.15 80 29.22
MEL_W 10 min 3.55 3 37.82
MEL_W_PVA 10 min 2.96 48 64.73
MEL_W_PVA 50 min 0.126 12 82.16
The combined wet milling technology was suitable for preparation of micronized MEL without
the use of stabilizer and, depending on the milling time, of micronized and nanonized drug
particles-containing pre-dispersions in the presence of PVA. Milling in the presence of additive could be
the first step of pre-formulation and further formulation procedures. Decreased particle size (especially
accessing the nanosize range) and the amorphization of drug could ensure higher dissolution rate
and better bioavailability of poorly-water soluble drugs, though instability problems could occur in
the case of amorphous forms of materials. To check the stability of the systems further investigations
are needed.
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Because of the low need for dispersant medium, the combined method can be used for efficient
milling, and it is also suggested for the preparation of the pre-dispersions with micro- and nanosized
particles, and recommended for the development of particle size-controlled therapeutic systems.
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